Pharmacoeconomic Evaluation of Lenograstim

This publication has 24 references indexed in Scilit:

• A phase II study of recombinant human granulocyte-colony stimulating factor (rHuG-CSF, lenograstim) in the treatment of agranulocytosis in children.
  1994
• The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis
  Quality of Life Research, 1994
• The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review.
  1994
• Economic Analysis of Lenograstim in the Correction of Neutropenia Following Chemotherapy for Non-Hodgkinʼs Lymphoma
  PharmacoEconomics, 1994
• Economic Evaluation of Lenograstim (Glycosylated rHuG-CSF) in the Treatment of Inflammatory Breast Cancer for Germany and Italy
  PharmacoEconomics, 1994
• Haematopoietic growth factors and cancer therapy.
  1993
• Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer.
  1992
• A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
  Journal of Clinical Oncology, 1992
• RECOMBINANT GM-CSF IN PATIENTS WITH POOR GRAFT FUNCTION AFTER BONE-MARROW TRANSPLANTATION
  1990
• High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.
  Journal of Clinical Oncology, 1989